| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 83.9 | 94.0 |
| Net income | 2.9 | 9.5 |
| EPS (diluted, $ a share) | $0.02 | $0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -69.9% |
|---|---|
| Revenue, year on year | -10.7% |
| Operating margin | -0.5% |
10-Q filed with the SEC, NASDAQ: ADPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Adaptive Biotechnologies Corp: key numbers
- Share price
- $27.87Close, Nov 16
- Market cap
- $4.51B
- Shares outstanding
- 161.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Adaptive Biotechnologies Corp
All →Adaptive Biotechnologies President and COO Julie Rubinstein Sells $1.05M of Stock
Julie Rubinstein, President and COO, sold 35,228 shares of Adaptive Biotechnologies Corp at $28.93 to $31.22 a share (average $29.73) in 4 transactions, worth $1.05M in total between Nov 11, 2026 and Nov 13, 2026. Shares held after the trade: 377,802 (-2.9%).
- Value
- $1.05M
- Shares
- 35,228
- Average price
- $29.73
- Role
- President and COO
- Holding change
- -2.9%
- Trade date
- Nov 11, 2026 to Nov 13, 2026
Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky Sells $60K of Stock
Susan Bobulsky, Chief Commercial Officer, MRD, sold 1,875 shares of Adaptive Biotechnologies Corp at $32.00 a share, worth $60K in total on Nov 11, 2026. Shares held after the trade: 387,475 (-0.5%).
- Value
- $60K
- Shares
- 1,875
- Price
- $32.00
- Role
- Chief Commercial Officer, MRD
- Holding change
- -0.5%
- Trade date
- Nov 11, 2026
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $709K of Stock
Julie Rubinstein, President and COO, sold 23,762 shares of Adaptive Biotechnologies Corp at $28.87 to $30.58 a share (average $29.82) in 5 transactions, worth $709K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 377,802 (-0.5%).
- Value
- $709K
- Shares
- 23,762
- Average price
- $29.82
- Role
- President and COO
- Holding change
- -0.5%
- Trade date
- Nov 9, 2026 to Nov 10, 2026
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $954K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.78 to $27.88 a share (average $26.78) in 7 transactions, worth $954K in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 377,802 (-0.9%).
- Value
- $954K
- Shares
- 35,643
- Average price
- $26.78
- Role
- President and COO
- Holding change
- -0.9%
- Trade date
- Nov 4, 2026 to Nov 6, 2026
Adaptive Biotechnologies Financial Results
Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with $83.9 million in revenue and $2.8 million in net income. The company saw 44% growth in core MRD revenue (excluding milestones) and increased its full-year 2026 MRD revenue guidance. Management highlighted momentum in clonoSEQ testing and updated clinical guidelines for multiple myeloma as key growth drivers.
- Term
- Q3 2026
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”
Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies
Adaptive Biotechnologies President and COO Julie Rubinstein Sells $929K of Stock
Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.23 to $27.45 a share (average $26.06) in 5 transactions, worth $929K in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 377,802 (-3.0%).
- Value
- $929K
- Shares
- 35,643
- Average price
- $26.06
- Role
- President and COO
- Holding change
- -3.0%
- Trade date
- Oct 30, 2026 to Nov 3, 2026